| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | -100.0% | — |
| R&D Expense | $177K | -7.8% | -92.4% |
| SG&A Expense | $547K | -40.2% | -34.0% |
| Operating Income | -$724K | -343.8% | +77.1% |
| Net Income | -$683K | -303.9% | +77.8% |
| EPS (Basic) | -$0.21 | -290.9% | +89.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.7M | +11.5% | +42.8% |
| Total Assets | $3.7M | -10.5% | +41.9% |
| Current Liabilities | $1.4M | +7.0% | +46.1% |
| Total Liabilities | $1.4M | +7.0% | +46.1% |
| Stockholders' Equity | $3.6M | -12.3% | +36.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$979K | — | — |
| Financing Cash Flow | $2.1M | — | — |